Clinical trials: Oral Phase
Healthy
A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562
This study will determine the safety and tolerability of PF-06412562 given orally to healthy volunteers. To determine the optimal dose for future studies, the concentration of the drug over time will be determined by periodic…
- Trial name
- NCT01914796
- Testing
- PF-06412562
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Pfizer
Relapsed Advanced Lymphomas
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
- Trial name
- ADITI-1 (NCT06755450)
- Testing
- AUR112
- Where
- 19 sites in India
- Volunteers
- 40 people
- Sponsor
- Aurigene Discovery Technologies Limited
Ulcerative Colitis
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
- Trial name
- NCT05549323
- Testing
- PF-07054894
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Pfizer
Erosive Esophagitis
Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
The purpose of the study is to demonstrate the efficacy of vonoprazan (TAK-438) versus lansoprazole in the treatment of erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
- Trial name
- NCT02388724
- Testing
- Vonoprazan, Lansoprazole
- Where
- 64 sites in China, Malaysia and 2 more
- Volunteers
- 481 people
- Sponsor
- Takeda
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT01279473
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Colon Cancer
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor.
- Conditions
- Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
- Trial name
- NCT01068483
- Testing
- BKM120
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Adults
A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions
The purpose of this clinical trial is to compare the blood tafamidis concentration of healthy adult participants after taking two different forms of tafamidis by under fasted conditions.
- Trial name
- NCT07587697
- Testing
- Tafamidis
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers
The primary objective of this study is to investigate the safety and tolerability of AZD1704 following single ascending doses in healthy Japanese male and non-fertile female volunteers by assessment of adverse events (AEs), vital…
- Trial name
- NCT00736788
- Testing
- AZD1704
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
The purpose of this study is to evaluate the effect of itraconazole, phenytoin and gemfibrozil on the drug levels of BMS-986166 and its active metabolite BMT-121795.
- Trial name
- NCT04956627
- Testing
- BMS-986166, Itraconazole, Extended Phenytoin Sodium
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
McArdle Disease
A Study of the Safety of REN001 in Patients With McArdle Disease
The purpose of this study is to assess REN001 safety in subjects with McArdle Disease
- Trial name
- NCT04226274
- Testing
- REN001
- Where
- 2 sites in Spain, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Reneo Pharma Ltd
Healthy
A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin
The purpose of this clinical study is to learn about the safety and effects of the study medicine (PF-07054894) in healthy Japanese participants.
- Trial name
- NCT06327880
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Migraine Without Aura
Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura
This is a a multi-center, randomized, double-blind, parallel group, and placebo controlled, two-arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache without aura.
- Trial name
- NCT00959751
- Testing
- NXN-188
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- NeurAxon Inc.
Myeloid Leukemia, Philadelphia Positive
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs.
- Trial name
- NCT04925479
- Testing
- Asciminib Pediatric formulation group, Asciminib Adult formulation group
- Where
- 39 sites in United States, China and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Arthritis, Psoriatic
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
The main objective of this study is to compare the relative bioavailability, safety, and tolerability of extended-release and immediate-release apremilast formulations in healthy participants.
- Conditions
- Psoriasis, Arthritis, Psoriatic, Oral Ulcer
- Trial name
- NCT07908641
- Testing
- Apremilast XR, Apremilast IR
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Amgen
Eosinophilic Esophagitis
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis
- Trial name
- NCT05488405
- Testing
- Mesalamine Oral Product
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- Dr. Falk Pharma GmbH
Type 1 Diabetes Mellitus
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD)…
- Trial name
- NCT07889505
- Testing
- PS1
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Colon Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
The purpose of this study is to evaluate the efficacy, safety, and tolerability of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of oral mucositis in subjects with stage 2B and 3…
- Trial name
- NCT00393822
- Testing
- palifermin
- Volunteers
- 100 people
- Sponsor
- Amgen
Healthy
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
The main objective of this trial is to assess single dose drug exposure of several newly developed formulation prototypes of Nintedanib compared to Ofev® following oral administration.
- Trial name
- NCT05262751
- Testing
- Ofev®, Nintedanib formulation 1, Nintedanib formulation 2
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.
- Trial name
- NCT06917872
- Testing
- BI 1291583, erythromycin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers
Study to investigate the basic pharmacokinetics of BI 44370 BS, its metabolite CD 10419 BS, and 14C-radioactivity including mass balance, excretion pathways, and metabolism following a single oral administration of 200 mg [14C]BI…
- Trial name
- NCT02215772
- Testing
- BI 44370 BS
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim